CRSP
CRISPR Therapeutics·NASDAQ
--
--(--)
--
--(--)
3.90 / 10
Netural
Analyst coverage is 100% Buy, reflecting strong conviction, while money flow shows robust inflows in Small and Large categories despite negative overall trends. The combination implies positive sentiment and liquidity, supporting the bullish analyst view.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-30
InstitutionCitizens
Times predicted1
Historical Win Rate0.0%
What is the analyst consensus for CRSP?
- CRSP holds a Bearish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 3.90/10 (Netural).
